Andreas C.
- Country
- Denmark
- Department
- Klinisk forskningsenhed, Onkologisk Afdeling
Research Overview
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
- Phase 3 Study of Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer
- Evaluation of Tobemstomig, Tiragolumab, and Atezolizumab in Untreated Locally Advanced or Metastatic Urothelial Cancer Ineligible for Platinum Chemotherapy
Data & Insights
Has run more than one trial at 100 of 243 partner sites.
Specializations
Urological Oncology
The investigator specializes in advancing treatments for urothelial carcinoma, with particular emphasis on managing metastatic bladder cancer and muscle-invasive disease.
- Advanced Bladder Cancer Management
- Metastatic Disease Treatment
- Post-Radical Cystectomy Care
Their research encompasses various stages of urological cancers, from locally advanced to metastatic presentations.
Immunotherapy Applications
The investigator focuses on innovative immunotherapeutic approaches in urological cancers, including novel combinations of checkpoint inhibitors and targeted therapies.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
- Novel Immunological Agents
Their work explores multiple immunotherapy pathways and their therapeutic potential in urothelial cancer treatment.
Precision Medicine
The investigator is involved in developing personalized treatment approaches for urothelial cancer patients, incorporating biomarker-driven therapies and targeted treatments.
- Molecular Targeted Therapy
- Treatment Response Monitoring
- Therapeutic Innovation
Their research integrates advanced diagnostic methods with tailored therapeutic strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.